
Nov 16, 2026 · 23 min
Personalized vaccines cut melanoma recurrence risk
Finally, a Vaccine for Cancer
The episode examines how mRNA, genomic sequencing, and immunotherapy could move cancer treatment toward individualized vaccines while prevention remains years away.
- 1A personalized mRNA vaccine trained patients’ immune systems to recognize melanoma mutations and reduced recurrence risk by 42 percent over two years.
- 2The approach builds on a century of immunotherapy research, alongside advances in genome sequencing, checkpoint inhibitors, and mRNA manufacturing.
- 3Broader cancer applications and vaccines that prevent cancer before it forms remain promising, but costly and years from widespread use.
Don't miss
The trial result that personalized vaccination reduced melanoma recurrence risk by 42 percent over two years.
The brief
Health reporter Nina Agrawal explains why cancer vaccines are difficult: each tumor carries distinct mutations, requiring a treatment designed around one patient’s cancer.
In a two-year trial, patients receiving the personalized mRNA vaccine were 42 percent less likely to see melanoma return, with limited side effects and fewer metastatic cases.
The strategy rests on a century of immunotherapy research, from William Coley’s 1890s experiments to genome sequencing, checkpoint inhibitors, and modern mRNA manufacturing.
The central tension is scale: bespoke vaccines may extend beyond melanoma, but their expense and complexity complicate use in pancreatic, breast, and colon cancers.
The longer-term ambition is prevention before cancer forms, yet Nina Agrawal stresses that preventive cancer vaccines remain years away despite recent scientific progress.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.